ClinicalTrials.gg
RecruitingNCT07221838OCTAGONUpdated Apr 9, 2026

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

A Phase 4 interventional study of Oral Corticosteroid Tapering Schedule and Ravulizumab in Generalized Myasthenia Gravis and gMG, sponsored by Alexion Pharmaceuticals, Inc.. Recruiting at 12 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.

Planned enrollment
5th of 13
75 · median 20
Started
2026
with 1 other
Phase 4
Only one
of the 19
Primary completion
2027-08
later than 4 of 10 live
Registered
17th of 19
by date

Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is the 5th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 4, reaches primary completion later than 4 of the 10 other live ones, and was the 17th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myasthenia Gravis by AstraZeneca, or all of them as a file.
02

Study summary

This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab.

03

Conditions studied

  • Generalized Myasthenia Gravis
  • gMG

Keywords

  • Generalized myasthenia gravis
  • gMG
  • Glucocorticoid toxicity
  • Complement C5 inhibitor
  • Prednisone reduction
  • Cortisol monitoring
  • ravulizumab
  • corticosteroids
  • adrenal insufficiency
  • steroid sparing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged greater than 18 years and male or female
  • Clinical diagnosis of gMG
  • Receiving ravulizumab treatment prior to enrollment
  • Receipt of OCS therapy equivalent to a daily dose ≥ 7.5 mg of prednisone/prednisolone for ≥ 4 continuous weeks directly preceding enrollment
  • A participant of must have a negative highly sensitive pregnancy test (serum or urine, as required by local regulations) taken at Screening before OCS tapering begins.
  • Willing to sign

Exclusion criteria

Exclusion Criteria:

  • Concurrent participation in an interventional clinical trial.
  • History of chronic hypoadrenalism (ie, Addison's disease).
  • Use of concomitant OCS for comorbid conditions other than gMG
  • Receipt of a biologic for gMG (e.g., efgartigimod, rozanolixizumab, inebilizumab, rituximab, intravenous immunoglobulin) within 5 half-lives of enrollment
  • Pregnant, breastfeeding, or intending to conceive during the course of the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Oral Corticosteroid Tapering Schedule

    During the tapering period, participant will follow an Oral Corticosteroid tapering schedule until OCS tapering is complete

    Procedure: Oral Corticosteroid Tapering Schedule · Drug: Ravulizumab · Drug: Prednisone/Prednisolone

Interventions

  • ProcedureOral Corticosteroid Tapering Schedule

    During the tapering period, participant will follow an Oral Corticosteroid tapering schedule as applicable to the participant. The oral corticosteroid (prednisone/prednisolone) is provided as per standard medical care.

  • Patients being treated with intravenous ravulizumab as part of their standard medical care.

  • DrugPrednisone/Prednisolone

    Drug pages: Prednisone · Prednisolone

    Participants will continue with or be switched to prednisone/prednisolone as per standard medical care.

06

What researchers measure

Primary outcomes

  1. Proportion of Adult Participants With gMG Who Either: Discontinue Oral Corticosteroids (OCS) or Reduce Their Daily OCS Dosage ≤ 5 mg/day and Maintain this Status for ≥ 4 Weeks Without Clinical Deterioration of gMG

    Time frame: Up to approximately 32 weeks

Secondary outcomes

  1. Proportion of Adult Participants with gMG Who Discontinue OCS (0 mg/day), Sustained ≥ 4 Weeks Without Clinical Deterioration of gMG

    Time frame: Up to approximately 32 weeks

  2. Percentage Change From Daily OCS Dose (mg/day) at Baseline

    Time frame: Baseline, Up to approximately 32 weeks

  3. Change from Baseline in the Myasthenia Gravis Quality of Life-15 Revised (MG-QoL-15r) Score in Adult Participants with gMG

    Time frame: Baseline, Up to approximately 32 weeks

  4. Change from Baseline in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score in Adult Participants with gMG

    Time frame: Baseline, Up to approximately 32 weeks

  5. Cumulative Worsening Score per the Glucocorticoid Toxicity Index - Metabolic Domains (GTI-MD) in Adult Participants with gMG

    Time frame: Baseline up to approximately 32 weeks

  6. Aggregate Improvement Score per the GTI-MD in Adult Participants with gMG

    Time frame: Baseline up to approximately 32 weeks

07

Study locations

1 of 12 sites recruiting
  • Research Site
    Chicago, Illinois 60637, United States
    Not yet recruiting
  • Research Site
    Schaumburg, Illinois 60173, United States
    Not yet recruiting
  • Research Site
    Neptune City, New Jersey 07753, United States
    Not yet recruiting
  • Research Site
    Raleigh, North Carolina 27607, United States
    Recruiting
  • Research Site
    Knoxville, Tennessee 37920, United States
    Not yet recruiting
  • Research Site
    Bochum, 44789, Germany
    Not yet recruiting
  • Research Site
    Milan, 20122, Italy
    Not yet recruiting
  • Research Site
    Naples, 80131, Italy
    Not yet recruiting
  • Research Site
    Rome, 00189, Italy
    Not yet recruiting
  • Research Site
    Ibaraki, 305-8576, Japan
    Not yet recruiting
  • Research Site
    Kitakyushu-shi, 807-8555, Japan
    Not yet recruiting
  • Research Site
    Kumamoto, 860-8556, Japan
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Aug 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2025
First posted
Oct 28, 2025
StartActual
Mar 4, 2026
Primary completionEst.
Aug 27, 2027
CompletionEst.
Aug 27, 2027
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07221838
Responsible party
Sponsor
First posted
Oct 28, 2025
Start date
Mar 4, 2026
Primary completion
Aug 27, 2027 (estimated)
Completion
Aug 27, 2027 (estimated)
Last update
Apr 9, 2026

Study contacts

Alexion Pharmaceuticals, Inc. (Sponsor)
Contact
clinicaltrials@alexion.com
1-855-752-2356

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion